MENU
+Compare
ADAP
Stock ticker: NASDAQ
AS OF
Oct 21 closing price
Price
$0.05
Change
-$0.01 (-16.67%)
Capitalization
12.88M

ADAP Adaptimmune Therapeutics plc Forecast, Technical & Fundamental Analysis

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies... Show more

Industry: #Biotechnology
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ADAP with price predictions
Oct 21, 2025

Aroon Indicator for ADAP shows an upward move is likely

ADAP's Aroon Indicator triggered a bullish signal on October 17, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 124 similar instances where the Aroon Indicator showed a similar pattern. In of the 124 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for ADAP crossed bullishly above the 50-day moving average on September 25, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADAP advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .

ADAP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for ADAP moved out of overbought territory on October 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on October 20, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ADAP as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ADAP turned negative on October 20, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

ADAP moved below its 50-day moving average on October 20, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADAP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.921) is normal, around the industry mean (23.690). P/E Ratio (0.000) is within average values for comparable stocks, (54.778). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.163). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.234) is also within normal values, averaging (355.294).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ADAP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADAP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ADAP is expected to report earnings to rise 110.00% to -4 cents per share on November 05

Adaptimmune Therapeutics plc ADAP Stock Earnings Reports
Q3'25
Est.
$-0.04
Q2'25
Beat
by $0.03
Q1'25
Beat
by $0.09
Q4'24
Missed
by $0.02
Q3'24
Est.
$-0.01
The last earnings report on August 13 showed earnings per share of -1 cents, beating the estimate of -5 cents. With 109.80M shares outstanding, the current market capitalization sits at 12.88M.
A.I. Advisor
published General Information

General Information

a manufacturer of vaccines and cancer immunotherapy products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
60 Jubilee Avenue
Phone
+44 1235430000
Employees
449
Web
https://www.adaptimmune.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PDS54.81-0.03
-0.05%
Precision Drilling Corp
NTRS128.52-0.33
-0.26%
Northern Trust Corp
DFLI1.21-0.05
-3.97%
Dragonfly Energy Holdings Corp
PBF28.06-1.45
-4.91%
PBF Energy
INTS0.26-0.02
-8.15%
Intensity Therapeutics

ADAP and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with AKBA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
-17.63%
AKBA - ADAP
41%
Loosely correlated
-1.27%
ORMP - ADAP
36%
Loosely correlated
+2.18%
CSLLY - ADAP
32%
Poorly correlated
-0.20%
AXON - ADAP
31%
Poorly correlated
+3.50%
NTLA - ADAP
31%
Poorly correlated
-3.61%
More